Silk Road Medical IPO Receiving Strong Interest, Gets Highest Rating

Acquisitions

▤ Summary

It gave Silk Road a rare rating of 5, or "strongest buy," at the IPO price. It uses minimally-invasive technology "to safely and effectively treat carotid artery disease, one of the leading causes of stroke," the company said in its . "We believe a total annual U.S. market opportunity of approximately $2.6 billion exists for our portfolio of TCAR products," it said. Investors include Warburg Pincus, Vertical Group Norwest Venture Partners and Janus. Please follow Brian Deagon on Twitter at @IBD_BDeagon for more on tech stocks, analysis and financial markets.

▥ Classifications

industries
No industries detected
applications
EduTech - learning

◇ AskAI Classifications

Labels
Human Resources Software Talent Management Recruitment Software

▦ Linked Companies